XOMAO

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

03/19 04:05 pm

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

03/08 08:30 am

XOMA to Present at Upcoming Investor Conferences in March

02/28 08:30 am

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

02/16 09:00 am

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

01/18 09:30 am

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

01/11 05:05 pm

XOMA Announces Stock Repurchase Program of up to $50 Million

01/02 08:30 am

XOMA Declares Quarterly Preferred Stock Dividends

12/20 08:30 am

I'm Buying Preferred Stocks Hand Over Fist

12/15 09:30 am

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

11/07 08:30 am

XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

10/31 07:30 am

XOMA Declares Quarterly Preferred Stock Dividends

09/25 07:30 am

XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference

09/06 07:30 am

XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

08/08 07:30 am

XOMA Added to the Russell 2000® and Russell 3000® Indexes

06/23 06:14 pm

XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset

06/22 07:30 am

XOMA Declares Quarterly Preferred Stock Dividends

06/20 07:30 am

I Put Half Of My Retirement Savings Into These Investments

09/02 08:35 am